(Q50078015)

24 February 2018

title

Safety evaluation of alpha-lipoic acid (ALA). (English)

1 reference

24 February 2018

author name string

Cremer DR

1

1 reference

24 February 2018

Rabeler R

2

1 reference

24 February 2018

Roberts A

3

1 reference

24 February 2018

Lynch B

4

1 reference

24 February 2018

language of work or name

English

0 references

publication date

14 August 2006

1 reference

24 February 2018

Regulatory Toxicology and Pharmacology

published in

1 reference

24 February 2018

volume

46

1 reference

24 February 2018

issue

1

1 reference

24 February 2018

page(s)

29-41

1 reference

24 February 2018

Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

The pharmacology of the antioxidant lipoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Alpha-lipoic acid mitigates insulin resistance in Goto-Kakizaki rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Dose-proportionality of oral thioctic acid--coincidence of assessments via pooled plasma and individual data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Long-term safety of alpha-lipoic acid (ALA) consumption: A 2-year study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Prevention of hypertension, insulin resistance, and oxidative stress by alpha-lipoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Acute, subacute and chronic toxicities of thioctic acid in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Mutagenicity spectra in Salmonella typhimurium strains of glutathione, L-cysteine and active oxygen species.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

K-region oxides and related oxidized metabolites of carcinogenic aromatic hydrocarbons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Lipoic acid is 10 times more toxic in cats than reported in humans, dogs or rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Thioctic acid--effects on insulin sensitivity and glucose-metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

The antihyperglycemic drug alpha-lipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation: potential role of p38 mitogen-activated protein kinase in GLUT4 activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Utilization of the insulin-signaling network in the metabolic actions of alpha-lipoic acid-reduction or oxidation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Do mammalian cells synthesize lipoic acid? Identification of a mouse cDNA encoding a lipoic acid synthase located in mitochondria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

alpha-Lipoic acid as a biological antioxidant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Interactions of exercise training and alpha-lipoic acid on insulin signaling in skeletal muscle of obese Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

The metabolism of dl-[1, 6-14C]lipoic acid in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Plasma Kinetics, Metabolism, and Urinary Excretion of Alpha‐Lipoic Acid following Oral Administration in Healthy Volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Influence of alpha-lipoic acid on lipid peroxidation and antioxidant defence system in blood of insulin-resistant rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Cardiac lipids and antioxidant status in high fructose rats and the effect of alpha-lipoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Lipoic acid attenuates hypertension and improves insulin sensitivity, kallikrein activity and nitrite levels in high fructose-fed rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Lipoic acid in multiple sclerosis: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YRTPH.2006.06.004

10.1016/J.YRTPH.2006.06.004

7 January 2021

Identifiers

DOI

1 reference

24 February 2018

PubMed ID

16904799

1 reference

24 February 2018